New data released from Leo Pharma indicates that their biologic drug tralokinumab-ldrm improved quality of life, anxiety, itching, depression and sleep disturbances for teens with atopic dermatitis between 12-17 years of age. The results, presented at the Western Society of Allergy, Asthma & Immunology (WSAAI) 59th Annual Scientific Session in Maui, are based on patient-reported outcomes at week 16 of the drug's one-year phase 3 clinical trial.
According to HCP Live, “A total of 100 patients received 150 mg of tralokinumab-ldrm, while 101 received 300 mg of the biologic. Investigators observed that siginificantly more adolescent patients achieved improvements with the biologic every 2 weeks compared to the 100 patients who received placebo.”
Click here to learn more.
(Source: HCP Live, February 17th, 2022)
